ivWatch said this week that it landed an international partner to manage the distribution of its continuous intravenous monitoring device.
The Hampton, Va.-based company inked a deal with supplier New Medical to distribute its ivWatch Model 400 system in Australia and New Zealand.
ivWatch’s sensor, which is roughly the size of a pencil eraser, uses light to measure the optical density of the tissue surrounding an IV insertion site, monitoring the flow of fluid as it moves into a person’s vein.
The device is designed to monitor the intravenous delivery of fluids for infiltrations.
“Our entry into these markets is a response to growing awareness and clinical demand,” Scott Hensley, VP of sales & business development, said in prepared remarks. “We are now poised to meet the ongoing customer requests for our technology as they seek cutting-edge solutions to address the global problem of patient harm caused by peripheral IV infiltration.”
“Australia is home to vascular access leaders who are undertaking significant scientific research focused on combating IV therapy complications internationally,” Paul Williams, director of New Medical, added. “We’re excited to put our technical teams in place to serve the needs of our customers. Our progressive health care market is equipped to make reliable early detection and notifications of this common IV complication a part of their efforts toward improving patient safety and outcomes.”
